The Claim
In adults with overweight or obesity, established cardiovascular disease, and no diabetes, once-weekly subcutaneous semaglutide 2.4 mg reduces the risk of a composite kidney outcome—defined as death from kidney disease, initiation of chronic kidney replacement therapy, persistent eGFR <15 ml/min/1.73m², persistent ≥50% eGFR reduction, or onset of persistent macroalbuminuria—by 22%, based on a hazard ratio of 0.78 observed over a median follow-up of 182 weeks in a randomized controlled trial involving 17,604 participants.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Taking a weekly semaglutide shot might help protect the kidneys in people with extra weight and heart disease—even if they don’t have diabetes.
See the scientific wording
Once-weekly subcutaneous semaglutide 2.4 mg likely reduces the risk of a composite kidney outcome—defined as death from kidney disease, initiation of chronic kidney replacement therapy, persistent eGFR <15 ml/min/1.73m², persistent ≥50% eGFR reduction, or onset of persistent macroalbuminuria—by 22% in adults with overweight or obesity, established cardiovascular disease, and no diabetes, based on a hazard ratio of 0.78 over a median follow-up of 182 weeks in a randomized controlled trial of 17,604 participants.
What the research says
1 studyStudy: Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
The study tested the same drug, in the same type of people, for the same kidney benefits, and found it worked just as well as claimed.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.